As shown in STAT’s Obesity Drug Tracker, Regeneron and others are using RNA interference to target genetics, rather than hormones like GLP-1. Skip to Main Content. FDA. Gene therapy.

Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA ...

First-in-human Phase 1a/1b clinical trial will evaluate orally available, RGT-61159 designed to selectively target MYB RNA and inhibit oncogenic MYB protein production Preclinical data supporting ...

Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve the treatment of cancer, cardiovascular and other complex diseases.

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological ...

A presentation titled RGT-61159, a Potent and Selective Small Molecule MYB RNA Inhibitor, Showed Significant Anti-Tumor Activity as Monotherapy or in Combination with Standards of Care in Several ...

WOBURN, Mass. , May 14, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA ...

WOBURN, Mass. , May 14, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA ...

Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage ...